Brazil’s ANVISA Introduces New Rules on Drug labeling with RDC 768/22

As of July, the new regulatory framework for drug labeling, the RDC 768/22, from the National Health Surveillance Agency (Anvisa), comes into effect.
Brazil’s Anvisa approves eighth cannabis-based medicinal product

Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are eight cannabis products approved by ANVISA.
Brazil’s Anvisa Updates the List of Brazilian Common Appellations

The Resolution RDC No. 590/2021 published on December 29th, 2021, the List of Brazilian Common Denominations (DCBs). The regulation included 28 new designations and changed two.
Brazil’s Anvisa approves eighth cannabis-based medicinal product

Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are eight cannabis products approved by ANVISA.
Brazil’s Anvisa identifies positive Covid-19 case in Brazilian passenger from South Africa

The Ordinance No.660/2021 It would impose restrictions on exceptional and specific restrictions, measures and requirements for entry into the country, due to the risks of contamination and dissemination of the SARS-CoV-2 coronavirus (covid-19).
Brazil’s Anvisa approves two new cannabis-based products

The Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are seven cannabis products approved by ANVISA.